An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.
Small Cell Lung Cancer|Non-small Cell Lung Cancer|Cervical Cancer|Ovarian Cancer|Gastric Cancer (Inoperable and Recurrent)
DRUG: CPT-11|DRUG: Platinum analogues
Number of Participants with UGT1A1 Genotype with Severe Toxicities Induced by CPT-11 with Platinum Analogues, within 6 months
Response Rate of Participants with UGT1A1 genotype to CPT-11 with Platinum Analogues, within 6 months|Duration of Response to CPT-11 with Platinum Analogues in Participants with UGT1A1 Genotype, within 6 months
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.